/ WHAT YOU WILL RECEIVE
Real photographs of your peptides, boxed, lot-labeled, and shipped in plain unmarked packaging from our partner research lab.
More batch photos and lab footage coming soon.
PEPTIDE SEQUENCE · STRUCTURE NOTE
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
Cyclic 7-residue melanocortin agonist (active metabolite of Melanotan II), lactam bridge between Asp² and Lys⁷, primary affinity for MC4R / MC3R / MC1R.
⏱ HALF-LIFE · PHARMACOKINETIC PROFILE
Melanocortin agonist (MC4R / MC3R / MC1R)
~2 hours
Short half-life · typically dosed pre-event for libido research.
Healing Peptides · RESEARCH GRADE
PT-141 (Bremelanotide)
10mg · Lyophilized Vial
Cyclic 7-residue melanocortin agonist, 10mg research vial for libido / arousal pathway studies.
UNIT PRICE
$40 USD
≈ CA$55
Reconstitution required
This compound requires bacteriostatic water for reconstitution. Don't forget to add a 10mL vial of BAC water to your order, available in Lab Supplies.
HOW LONG WILL IT LAST YOU?
Enter your research protocol and vial quantity — see exactly how many weeks your order covers.
Each 10mg vial lasts
10 weeks
Your 10mg vial lasts
10weeks
≈ 70 days · 10 doses per vial
FOR RESEARCH USE ONLY
Not for human consumption. Intended for laboratory and in-vitro research applications./ RESEARCH DOSSIER
Everything we know
about PT-141.
Direct from the research literature. Every section is sourced from peer-reviewed peptide studies and clearly labelled when effects come from animal or cell-line models.
/ 01 · WHAT WE KNOW
The background.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and active metabolite of Melanotan II. It non-selectively activates melanocortin receptors, primarily MC4R in the central nervous system, bypassing the vascular pathway used by PDE5 inhibitors. Bremelanotide is the only FDA-approved (Vyleesi) on-demand non-hormonal arousal therapy for premenopausal hypoactive sexual desire research.
/ 02 · WHAT IT DOES FOR YOU
What researchers study it for.
Researchers study PT-141 for centrally-mediated libido and arousal response, female HSDD models, and cases where vascular ED treatments (sildenafil, tadalafil) are insufficient or contraindicated. Onset is typically 30 to 60 minutes; effect lasts 6 to 12 hours.
RESEARCH HIGHLIGHTS · published animal & cell-model studies
- ▸Centrally-mediated libido / arousal research
- ▸FDA-approved (Vyleesi) for premenopausal HSDD
Sourced from peer-reviewed research literature. Effects described are from animal & cell-line models unless otherwise noted. For research use only.
/ 03 · HOW IT WORKS
Mechanism of action.
Biological pathways identified in the research literature for PT-141.
Centrally-mediated MC4R agonism → arousal pathway
Bypasses vascular pathway used by PDE5 inhibitors
/ 04 · OVERVIEW & CLASSIFICATION
Classification.
Cyclic 7-residue melanocortin agonist (active metabolite of Melanotan II), central libido / arousal pathway.
TYPE
Cyclic heptapeptide MC agonist
DERIVATION
Synthetic with Asp²-Lys⁷ lactam cyclization.
STRUCTURE
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂.
/ 05 · PHARMACOLOGICAL PROFILE
Pharmacology.
HALF-LIFE
~2.7 hours
ABSORPTION
SC, intranasal
DISTRIBUTION
CNS-penetrant
/ 06 · DOSAGE & RECONSTITUTION
Research dosing protocols.
/ 07 · PAIRS WELL WITH
Researched stacks.
Compounds explored alongside PT-141 in the published literature.
PT-141 + PDE5 inhibitor research = central + vascular pathway coverage
PT-141 acts on the central MC4R arousal pathway, while PDE5 inhibitors act on peripheral vasodilation. Together they cover both arms of the arousal-response axis in research models, useful when isolating which pathway is dominant in a given subject.
/ 08 · SAFETY PROFILE
Safety notes.
- ▸Common: flushing, nausea (dose-dependent)
- ▸BP elevation possible
Research use only · not for human consumption · always consult published literature before designing any research protocol.